Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. eHealth-mind the gap

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To identify a failure site-specific prognostic model by combining immunohistochemistry (IHC) and molecular imaging information to predict long-term failure type in squamous cell carcinoma of the head and neck.

PATIENT AND METHODS: Tissue microarray blocks of 196 head and neck squamous cell carcinoma cases were stained for a panel of biomarkers using IHC. Gross tumor volume (GTV) from the PET/CT radiation treatment planning CT scan, maximal Standard Uptake Value (SUVmax) of fludeoxyglucose (FDG) and clinical information were included in the model building using Cox proportional hazards models, stratified for p16 status in oropharyngeal carcinomas. Separate models were built for time to locoregional failure and time to distant metastasis.

RESULTS: Higher than median p53 expression on IHC tended toward a risk factor for locoregional failure but was protective for distant metastasis, χ(2) for difference p = .003. The final model for locoregional failure included p53 (HR: 1.9; p: .055), concomitant cisplatin (HR: 0.41; p: .008), β-tubulin-1 (HR: 1.8; p: .08), β-tubulin-2 (HR: 0.49; p: .057) and SUVmax (HR: 2.1; p: .046). The final model for distant metastasis included p53 (HR: 0.23; p: .025), Bcl-2 (HR: 2.6; p: .08), SUVmax (HR: 3.5; p: .095) and GTV (HR: 1.7; p: .063).

CONCLUSIONS: The models successfully distinguished between risk of locoregional failure and risk of distant metastasis, which is important information for clinical decision-making. High p53 expression has opposite prognostic effects for the two endpoints; increasing risk of locoregional failure, but decreasing the risk of metastatic failure, but external validation of this finding is needed.

OriginalsprogEngelsk
TidsskriftActa oncologica
Vol/bind56
Udgave nummer11
Sider (fra-til)1562-1570
ISSN0284-186X
DOI
StatusUdgivet - 2017

ID: 51769840